Cardio Diagnostics Holdings, Inc., an AI-driven precision cardiovascular medicine company announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee.
Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity. He is also the CEO of Akan Biosciences, a clinical-stage biotech company, and runs an advisory firm working closely with healthcare growth companies. Mr. Burton brings over 20 years of experience in medical technology innovation, corporate finance, and shaping the strategy and operations of growth-stage companies.
Before 2Flo Ventures, Mr. Burton was CEO of several venture-backed companies developing novel therapeutics. He began his career in investment banking at Citigroup, executing over $14 billion in M&A and financing transactions. Mr. Burton holds J.D. and MBA degrees from the University of Illinois Urbana-Champaign. Over the years, he has helped raise more than $6 billion for more than 20 companies. He has particular expertise in FDA navigation for companies building novel therapeutics and medical technologies.
“We are thrilled to welcome Paul to Cardio Diagnostics’ Board of Directors,” said CEO and Co-Founder Meesha Dogan, PhD. “His breadth of expertise and established track record spanning healthcare investing, growth strategy, corporate transactions, and operating biotechnology companies will be invaluable. Paul shares our vision of using advanced diagnostics for more personalized cardiovascular care and we look forward to leveraging his insights and expertise to grow Cardio Diagnostics’ footprint towards becoming the new standard of cardiovascular care.”
“I am thrilled to join the Cardio Diagnostics board to help drive the next wave of cardiovascular innovation,” said Paul Burton, J.D., MBA, Managing Partner at 2Flo Ventures. “With its groundbreaking AI-enabled technology, Cardio has enormous potential to transform the detection, management and prevention of heart disease. The company’s progress has been impressive, and I look forward to collaborating closely with Cardio’s exceptional leadership team to help accelerate the company’s growth.”
Source: Cardio Diagnostics Holdings
